<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04240951</url>
  </required_header>
  <id_info>
    <org_study_id>PEP-1714</org_study_id>
    <nct_id>NCT04240951</nct_id>
  </id_info>
  <brief_title>Sweat Patch Validation</brief_title>
  <official_title>Validity of a Prototype Wearable Patch in Measuring Local Sweating Rate and Sweat Electrolyte Concentration During Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PepsiCo Global R&amp;D</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PepsiCo Global R&amp;D</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the validity of a prototype patch in measuring sweating rate and sweat&#xD;
      electrolyte concentration during moderate intensity exercise against well-established&#xD;
      reference methods in a controlled laboratory and in field conditions.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Actual">October 24, 2020</completion_date>
  <primary_completion_date type="Actual">October 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Each subject subject serves as their own control at each testing session. The prototype patch and reference method are both worn during each session.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sweat chloride concentration</measure>
    <time_frame>1.5 hours in sessions 1-6</time_frame>
    <description>Prototype vs. reference method (regional absorbent patch technique) during exercise</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Regional sweating rate</measure>
    <time_frame>1.5 hours in sessions 1-6</time_frame>
    <description>Prototype vs. reference method (gravimetry using the regional absorbent patch technique) during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body sweating rate</measure>
    <time_frame>1.5 hours in sessions 1-6</time_frame>
    <description>Prototype vs. reference method (changes in nude body mass corrected for fluid intake, urine output, respiratory water loss, and metabolic mass loss) during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body sweat chloride concentration</measure>
    <time_frame>1.5 hours in sessions 3-4</time_frame>
    <description>Prototype vs. reference method (whole body washdown technique) during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body sweat sodium concentration</measure>
    <time_frame>1.5 hours in sessions 3-4</time_frame>
    <description>Reference method only. Compare whole body sweat chloride concentration vs. whole body sweat sodium concentration during exercise</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-ratings of perceived sweating vs. measured sweating rate</measure>
    <time_frame>Prior to the start of exercise at sessions 1-6</time_frame>
    <description>Multiple choice questionnaire vs. sweat patch analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-ratings of perceived sweat saltiness vs. sweat electrolyte concentrations</measure>
    <time_frame>Prior to the start of exercise at sessions 1-6</time_frame>
    <description>Multiple choice questionnaire vs. sweat patch analysis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>History of exercise-associated muscle cramps</measure>
    <time_frame>Prior to the start of exercise at sessions 1-6</time_frame>
    <description>Multiple choice questionnaire</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">552</enrollment>
  <condition>Sweat Analysis</condition>
  <arm_group>
    <arm_group_label>Study Session 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the laboratory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Session 2 (repeat of Study Session 1)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm Type: Validation: Regional sweat collection with prototype vs. reference patch in the laboratory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Session 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Session 4 (repeat of Study Session 3)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm Type: Validation. Prototype patch vs. whole body sweat collection in the laboratory</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Session 5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Session 6 (repeat of Study Session 5)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Arm Type: Validation. Regional sweat collection with prototype vs. reference patch in the field</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sweat patch</intervention_name>
    <description>Flexible, epidermal, wearable skin patch to collect and analyze sweat</description>
    <arm_group_label>Study Session 1</arm_group_label>
    <arm_group_label>Study Session 2 (repeat of Study Session 1)</arm_group_label>
    <arm_group_label>Study Session 3</arm_group_label>
    <arm_group_label>Study Session 4 (repeat of Study Session 3)</arm_group_label>
    <arm_group_label>Study Session 5</arm_group_label>
    <arm_group_label>Study Session 6 (repeat of Study Session 5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is male or female&#xD;
&#xD;
          -  Subject is 15-45 years&#xD;
&#xD;
          -  Subject is moderately-trained (engages in moderate-intensity, intermittent, or&#xD;
             steady-state exercise at least 4 days per week for at least 1 hour at a time)&#xD;
&#xD;
          -  Subject is capable of moderate-intensity, intermittent exercise for 1-2 hours as&#xD;
             assessed by recent training history&#xD;
&#xD;
          -  If participating in Study Session 1, 2, 3, or 4, subject has a treadmill VO2max ≥ 42&#xD;
             ml/kg/min if male or ≥ 38 ml/kg/min if female, as measured during the screening at the&#xD;
             GSSI laboratory&#xD;
&#xD;
          -  If participating in Study Session 1, 2, 3, or 4, subject has a normal fasting blood&#xD;
             glucose (70-110 mg/dl), as measured during the screening at the GSSI laboratory&#xD;
&#xD;
          -  If participating in Study Session 1, 2, 3, or 4, subject has a normal resting blood&#xD;
             pressure (&lt; 140/90 mmHg), as measured during the screening at the GSSI laboratory&#xD;
&#xD;
          -  If participating in Study Session 1, 2, 3, or 4, subject has a normal resting and&#xD;
             graded exercise EKG, as measured during the screening at the GSSI laboratory&#xD;
&#xD;
          -  If participating in Study Session 1, 2, 3, or 4, willing to be shaved at patch sites&#xD;
&#xD;
          -  If participating in Study Session 3 or 4, willing to undergo a nude shower by an&#xD;
             investigator of the same sex for collection of sweat electrolytes in the whole body&#xD;
             wash procedure&#xD;
&#xD;
          -  If participating in Study Session 5 or 6, subject is a trained team-sport athlete&#xD;
             currently participating in training/competition at IMG Academy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant (self-reported)&#xD;
&#xD;
          -  Subject is a smoker&#xD;
&#xD;
          -  Subject has a body weight that is lighter than 80 pounds&#xD;
&#xD;
          -  Subject has a known or suspected obstructive disease of the gastrointestinal tract,&#xD;
             such as diverticulitis or inflammatory bowel disease&#xD;
&#xD;
          -  Subject has a history of problems with the gag reflex&#xD;
&#xD;
          -  Subject has not had previous gastrointestinal surgery&#xD;
&#xD;
          -  Subject has problems with swallowing&#xD;
&#xD;
          -  Subject is planning to have an MRI scan during the time that the CorTemp™ Core Body&#xD;
             Temperature Sensor is in the body&#xD;
&#xD;
          -  Subject has slow movement of the gastrointestinal tract&#xD;
&#xD;
          -  Subject has a cardiac pacemaker or other implanted electronic device&#xD;
&#xD;
          -  Subject has asthma or other condition in which breathing can become difficult/labored&#xD;
             during exercise (applies to Study Session 1-4 only)&#xD;
&#xD;
          -  Subject is allergic to adhesives&#xD;
&#xD;
          -  Subject is currently taking a medication or oral supplement that could interfere with&#xD;
             study results&#xD;
&#xD;
          -  Subject has a condition the investigator believes would interfere with his/her ability&#xD;
             to provide informed consent, comply with the study protocol, which might confound the&#xD;
             interpretation of the study results or put the person at undue risk&#xD;
&#xD;
          -  Subject has been enrolled into a PepsiCo-sponsored study within the past six months&#xD;
&#xD;
          -  Subject has been enrolled into a clinical trial at a laboratory or clinic other than&#xD;
             PepsiCo within the past 30 days&#xD;
&#xD;
          -  Subject is employed by, or has a parent, guardian or other immediate family member&#xD;
             employed by, a company that manufactures any products that compete with any Gatorade&#xD;
             products. If subject is unsure if a company would be considered a competitor to&#xD;
             Gatorade they will be asked to please let the study investigator know the name of the&#xD;
             other company and the nature of their relationship to that company before they sign&#xD;
             the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lindsay B Baker, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PepsiCo Global R&amp;D, Gatorade Sports Science Institute (GSSI) PI for Barrington site</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Khalil Lee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PepsiCo Global R&amp;D, Gatorade Sports Science Institute (GSSI) PI for Bradenton site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gatorade Sports Science Institute at IMG Academy</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gatorade Sports Science Institute (GSSI)</name>
      <address>
        <city>Barrington</city>
        <state>Illinois</state>
        <zip>60010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 14, 2020</study_first_submitted>
  <study_first_submitted_qc>January 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sweating rate</keyword>
  <keyword>sweat electrolytes</keyword>
  <keyword>sweat patch</keyword>
  <keyword>wearable</keyword>
  <keyword>epidermal</keyword>
  <keyword>sweat electrolyte concentrations</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

